ESCP International Workshop Expanding roles and opportunities
for the pharmacist in optimizing use of oral cancer drugs. 19–20
February 2018, Reykjavik, Iceland
Ó Springer International Publishing AG, part of Springer Nature 2018
Improving knowledge of oral chemotherapy will help
pharmacists to counsel cancer patients
, M. Kand
, M. Urbala
, A. Eberl
Tartu University Hospital, Tartu,
North Estonian Medical Centre,
Institute of Ljubljana, Ljubljana, Slovenia
Background and Objective: More patients with cancer are being
treated with oral anticancer drugs and these agents are often dispensed
by community pharmacists. Several recent studies (Abbott 2014,
Suzuki 2017) have shown that pharmacists lack knowledge of oral
chemotherapy (OC) and demonstrated need for additional education
and training in OC.
Design: An educational programme was developed and introduced as
e-learning course for all pharmacists in Estonia within international
project EPIC (Empowering pharmacists to improve health care for
oral chemotherapy patients) lead by European Society of Oncology
Pharmacy. The programme is divided to three modules including
topics such as principles of chemotherapy, hormonal therapy and
targeted therapy; side-effects and their management; interactions with
medicines and food supplements; safe handling of chemotherapy etc.
Materials for e-training were prepared by multidisciplinary team
including oncology pharmacists, physicians and nurses. Every module
has to be completed by passing the test. The programme will run
April-December 2017. A survey was conducted before starting the
e-training to assess pharmacists’ conﬁdence in and knowledge to
counsel cancer patients on OC.
Results: 504 pharmacists (28% of all pharmacists working in phar-
macies in Estonia) were registered in e-training course; most of them
are working in the community pharmacies (88%). Participants had
different experience dispensing OC in their settings. 70% of phar-
macists dispense OC monthly or less than monthly; 18% have patients
with OC visiting their pharmacy daily or weekly. Only 3% of
respondents felt that they had received adequate training about OC
previously and 39% had attended some educational event related to
oncology in the past 2 years. However, majority of participants (97%)
stated that they lack conﬁdence in counselling patients with OC.
Conclusion: Pharmacists expressed great interest in the educational
activities organized within EPIC project. Introducing the training
programme could help pharmacists to get more knowledge about OC
and ensure that they could provide appropriate pharmaceutical care
for cancer patients receiving OC. Post educational survey should be
conducted to evaluate participants’ knowledge and attitudes after
completing the training.
This abstract is part of the project ‘664509/EPIC’ which has received
funding from the European Union’s Health Programme (2014–2020).
Disclosure of Interest: None Declared.
Therapeutic adherence of patients to dasatinib
or nilotinib with chronic myeloid leukemia in a Belgian
, D. Lesage
, S. Mertens
, A. Somers
Pharmacy, Ghent University Hospital, Gent, Belgium
Background and Objective: The success of oral therapy demands a
huge responsibility of the patient to take his medication as prescribed.
Studies with imatinib have proven that suboptimal responses were
signiﬁcantly higher in chronic myeloid leukaemia (CML) patients
with adherence rates below 90%. The goal of this study was to
evaluate the therapeutic adherence of CML patients to the second
generation tyrosine kinase inhibitors dasatinib and nilotinib based on
the prescription reﬁlls in the pharmacy of the Ghent University
Setting and Method: The Medication Possession Ratio (MPR) was
calculated for dasatinib and nilotinib delivered from 1/1/2013 until
29/2/2016 to CML patients treated in UZ Gent.
Main outcome measures: Therapeutic adherence determined by the
Medication Possession Ratio.
Results: A total of 48 treatment periods have been evaluated, 18 with
nilotinib and 30 with dasatinib. The duration of the treatment periods
varied from 24 to 1164 days. MPRs between 90 and 110% were
calculated for 8 (44.4%) nilotinib treatments and 12 (40.0%) dasatinib
treatments. MPRs below 90% were observed in 5 (27,8%) nilotinib
Int J Clin Pharm (2018) 40:730–736